$198.83
+0.18
(+0.09%)▲
Revenue is up for the last 2 quarters, 653.0K → 1.10M (in $), with an average increase of 40.9% per quarter
Netprofit is down for the last 11 quarters, -6.94M → -40.87M (in $), with an average decrease of 20.8% per quarter
0.1%
Downside
Day's Volatility :0.11%
Upside
0.01%
88.78%
Downside
52 Weeks Volatility :88.79%
Upside
0.08%
Period | Ignyta, Inc. | Sector (Health Care) | Index (Russel 2000) |
---|---|---|---|
3 Months | 58.14% | 0.9% | -8.3% |
6 Months | 427.12% | -6.8% | -6.5% |
1 Year | 614.96% | 0.4% | -6.1% |
3 Years | 686.2% | 27.3% | 21.8% |
Market Capitalization | 9.5B |
Book Value | $14.62 |
Dividend Share | 0.0 |
Dividend Yield | 0.0% |
Earnings Per Share (EPS) | -3.54 |
Wall Street Target Price | 195.0 |
Profit Margin | 0.0% |
Operating Margin TTM | -4064.73% |
Return On Assets TTM | -20.06% |
Return On Equity TTM | -33.3% |
Revenue TTM | 4.0M |
Revenue Per Share TTM | 0.09 |
Quarterly Revenue Growth YOY | -71.8% |
Gross Profit TTM | -106.0M |
EBITDA | -161.6M |
Diluted Eps TTM | -3.54 |
Quarterly Earnings Growth YOY | 0.0 |
EPS Estimate Current Year | -3.9 |
EPS Estimate Next Year | -4.31 |
EPS Estimate Current Quarter | -0.91 |
EPS Estimate Next Quarter | -0.96 |
What analysts predicted
Downside of 1.93%
FY19 | Y/Y Change | |
---|---|---|
Revenue | 1.1M | - |
Net Income | -29.7M | - |
Net Profit Margin | -2.7K% | - |
FY20 | Y/Y Change | |
---|---|---|
Revenue | 1.2M | ↑ 9.93% |
Net Income | -37.1M | ↑ 24.95% |
Net Profit Margin | -3.0K% | ↓ 363.22% |
FY21 | Y/Y Change | |
---|---|---|
Revenue | 3.1M | ↑ 154.6% |
Net Income | -90.2M | ↑ 142.86% |
Net Profit Margin | -2.9K% | ↑ 139.26% |
FY22 | Y/Y Change | |
---|---|---|
Revenue | 6.8M | ↑ 117.61% |
Net Income | -141.8M | ↑ 57.16% |
Net Profit Margin | -2.1K% | ↑ 800.72% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Revenue | -295.0K | ↓ 129.32% |
Net Income | -29.9M | ↑ 9.46% |
Net Profit Margin | 10.1K% | ↑ 12858.69% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Revenue | 3.9M | ↓ 1428.47% |
Net Income | -32.1M | ↑ 7.18% |
Net Profit Margin | -818.22% | ↓ 10959.91% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Revenue | 1.3M | ↓ 67.62% |
Net Income | -33.6M | ↑ 4.93% |
Net Profit Margin | -2.7K% | ↓ 1833.24% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Revenue | 968.0K | ↓ 23.72% |
Net Income | -37.3M | ↑ 10.78% |
Net Profit Margin | -3.9K% | ↓ 1199.26% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Revenue | 653.0K | ↓ 32.54% |
Net Income | -38.8M | ↑ 3.99% |
Net Profit Margin | -5.9K% | ↓ 2085.57% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Revenue | 1.1M | ↑ 69.22% |
Net Income | -40.9M | ↑ 5.45% |
Net Profit Margin | -3.7K% | ↑ 2237.1% |
FY16 | Y/Y Change | |
---|---|---|
Total Assets | 144.9M | ↓ 26.12% |
Total Liabilities | 50.1M | ↓ 16.65% |
FY19 | Y/Y Change | |
---|---|---|
Total Assets | 50.5M | - |
Total Liabilities | 87.5M | - |
FY20 | Y/Y Change | |
---|---|---|
Total Assets | 59.6M | ↑ 18.12% |
Total Liabilities | 157.2M | ↑ 79.73% |
FY21 | Y/Y Change | |
---|---|---|
Total Assets | 267.8M | ↑ 349.08% |
Total Liabilities | 32.6M | ↓ 79.23% |
FY22 | Y/Y Change | |
---|---|---|
Total Assets | 740.8M | ↑ 176.61% |
Total Liabilities | 64.8M | ↑ 98.51% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Total Assets | 267.8M | ↓ 7.32% |
Total Liabilities | 32.6M | ↑ 21.64% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 253.6M | ↓ 5.31% |
Total Liabilities | 46.9M | ↑ 43.53% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 237.6M | ↓ 6.31% |
Total Liabilities | 45.8M | ↓ 2.35% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 298.6M | ↑ 25.69% |
Total Liabilities | 66.1M | ↑ 44.42% |
Q4 FY22 | Q/Q Change | |
---|---|---|
Total Assets | 740.8M | ↑ 148.07% |
Total Liabilities | 64.8M | ↓ 1.93% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Total Assets | 758.4M | ↑ 2.38% |
Total Liabilities | 60.8M | ↓ 6.18% |
FY18 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -6.1M | ↓ 93.23% |
Investing Cash Flow | -82.0K | - |
Financing Cash Flow | 10.1M | - |
FY19 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -20.2M | ↑ 231.15% |
Investing Cash Flow | 7.9M | ↓ 9774.39% |
Financing Cash Flow | 9.8M | ↓ 3.81% |
FY20 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -28.0M | ↑ 38.72% |
Investing Cash Flow | -1.1M | ↓ 113.4% |
Financing Cash Flow | 79.9M | ↑ 718.92% |
FY21 | Y/Y Change | |
---|---|---|
Operating Cash Flow | -63.5M | ↑ 126.66% |
Investing Cash Flow | -1.1M | ↑ 6.87% |
Financing Cash Flow | 267.7M | ↑ 235.1% |
Q4 FY21 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -22.2M | ↑ 30.63% |
Investing Cash Flow | -190.0K | ↓ 48.09% |
Financing Cash Flow | 505.0K | ↓ 106.37% |
Q1 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -29.4M | ↑ 32.52% |
Investing Cash Flow | -955.0K | ↑ 402.63% |
Financing Cash Flow | 123.0K | ↓ 75.64% |
Q2 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -28.8M | ↓ 1.84% |
Investing Cash Flow | -116.9M | ↑ 12136.96% |
Financing Cash Flow | 14.6M | ↑ 11798.37% |
Q3 FY22 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -53.3M | ↑ 84.71% |
Investing Cash Flow | -65.8M | ↓ 43.73% |
Financing Cash Flow | 72.2M | ↑ 393.56% |
Q1 FY23 | Q/Q Change | |
---|---|---|
Operating Cash Flow | -39.5M | ↓ 3.84% |
Investing Cash Flow | -192.3M | - |
Financing Cash Flow | 52.8M | ↓ 88.89% |
Sell
Neutral
Buy
Ignyta, Inc. is currently in a favorable trading position ( BUY ) according to technical analysis indicators.
Company Name | 1 Month | 6 Month | 1 Year | 3 Years | 5 Years |
---|---|---|---|---|---|
![]() Ignyta, Inc. | 2.34% | 427.12% | 614.96% | 686.2% | 686.2% |
![]() Moderna, Inc. | 0.28% | -25.82% | -4.84% | 117.92% | 601.67% |
![]() Regeneron Pharmaceuticals, Inc. | -7.87% | -2.05% | 17.39% | 22.45% | 137.1% |
![]() Seagen, Inc. | -1.61% | 61.18% | 39.62% | 26.01% | 217.64% |
![]() Vertex Pharmaceuticals Incorporated | -3.63% | 5.09% | 23.88% | 20.49% | 123.04% |
Company Name | P/E Ratio | P/B Ratio | PEG Ratio | EPS | ROE | ROA | Div Yield | BVPS |
---|---|---|---|---|---|---|---|---|
![]() Ignyta, Inc. | NA | NA | NA | -3.9 | -0.33 | -0.2 | 0.0 | 14.62 |
![]() Moderna, Inc. | 11.46 | 11.46 | 0.0 | -1.9 | 0.27 | 0.12 | 0.0 | 49.12 |
![]() Regeneron Pharmaceuticals, Inc. | 19.91 | 19.91 | 9.01 | 41.59 | 0.19 | 0.1 | 0.0 | 219.38 |
![]() Seagen, Inc. | NA | NA | 18.53 | -2.88 | -0.23 | -0.12 | 0.0 | 14.54 |
![]() Vertex Pharmaceuticals Incorporated | 26.18 | 26.18 | 0.41 | 14.61 | 0.26 | 0.17 | 0.0 | 56.05 |
Company Name | Analyst View | Market Cap | 5 Years Return % | PE Ratio | Profit Margin |
---|---|---|---|---|---|
![]() Ignyta, Inc. | Hold | $9.5B | 686.2% | NA | 0.0% |
![]() Moderna, Inc. | Buy | $49.1B | 601.67% | 11.46 | 31.77% |
![]() Regeneron Pharmaceuticals, Inc. | Buy | $80.7B | 137.1% | 19.91 | 33.81% |
![]() Seagen, Inc. | Hold | $36.5B | 217.64% | NA | -31.55% |
![]() Vertex Pharmaceuticals Incorporated | Buy | $83.3B | 123.04% | 26.18 | 35.4% |
RTW INVESTMENTS, LLC
BlackRock Inc
Vanguard Group Inc
Boxer Capital LLC
72 Investment Holdings, LLC
Cormorant Asset Management, LLC
Ignyta, Inc.’s price-to-earnings ratio stands at None
Read MorePrometheus Biosciences, Inc. is a biotechnology company pioneering a precision medicine approach for the discovery, development, and commercialization of novel therapeutic and companion diagnostic products for the treatment and diagnosis of IBD. The company's precision medicine platform, Prometheus360, combines proprietary bioinformatics discovery methods with one of the world's largest gastrointestinal bioinformatics databases to identify novel therapeutic targets and develop therapeutic candidates to engage those targets. Prometheus is headquartered in San Diego, CA.
Organization | Ignyta, Inc. |
Employees | 97 |
CEO | Mr. Mark C. McKenna |
Industry | Healthcare |
Green Brick Partners Inc
$51.14
+4.07%
International Select Dividend iShares
$26.99
+1.85%
Vipshop Holding Ltd.
$15.94
+5.7%
iShares MSCI KLD 400 Social ETF
$81.32
+1.57%
Grupo Televisa, S.A.B.
$4.88
+4.5%
Hawaiian Electric Industries Inc.
$36.79
+3.46%
Jinkosolar Holding Co., Ltd.
$42.26
+0.4%
Pampa Energia SA
$38.52
+0.34%
Allegro Microsystems, Inc.
$39.48
-0.03%